Xanomeline
![Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284](http://data.docslib.org/img/264x/44d9601a65f3e6260c873f2ec650b7ac.webp)
Top View
- Review 0103 - 5053 $6.00+0.00
- PIG&I* the USA. ALZHEIMER's DISEASE: CURRENT AND
- Allosteric Modulation of the Muscarinic M4 Receptor As an Approach to Treating Schizophrenia
- (12) Patent Application Publication (10) Pub. No.: US 2017/0095465 A1 Elenko Et Al
- Practice Parameter: Management of Dementia (An Evidence-Based Review)
- Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
- Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
- Molecular Mechanisms of Action and in Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties
- Muscarinic Acetylcholine Receptors: Novel Opportunities for Drug Development Andrew C
- Karuna Pharmaceuticals and Puretech Health Announce Positive Results
- Pharmacological Investigations on Muscarinic and P2 Receptor Subtypes
- Curriculum Vitae
- Muscarinic Acetylcholine Receptor
- Xanomeline (LY246708) Protocol H2Q-MC-LZZT(C)
- UNO Template
- Wo 2007/044693 A2
- Statistical Analysis Plan for Interventional Studies
- Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model